Darunavir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Darunavir |
| DrugBank ID | DB01264 |
| Brand Names (EU) | Prezista |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV?1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 99.98% | DL |
| 2 | feline acquired immunodeficiency syndrome | 99.97% | DL |
| 3 | simian immunodeficiency virus infection | 99.97% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.97% | DL |
| 5 | AIDS | 99.58% | DL |
| 6 | obsolete familial combined hyperlipidemia | 99.19% | DL |
| 7 | congenital human immunodeficiency virus | 98.97% | DL |
| 8 | AIDS related complex | 98.97% | DL |
| 9 | fibroma of prostate | 97.74% | DL |
| 10 | Brenner tumor | 97.53% | DL |
| 11 | benign reproductive system neoplasm | 97.52% | DL |
| 12 | benign prostate phyllodes tumor | 97.35% | DL |
| 13 | male reproductive organ cancer | 96.83% | DL |
| 14 | prostate cancer/brain cancer susceptibility | 96.25% | DL |
| 15 | prostate leiomyoma | 96.24% | DL |
| 16 | breast fibrocystic disease | 92.38% | DL |
| 17 | chronic hepatitis C virus infection | 91.23% | DL |
| 18 | benign mammary dysplasia | 91.05% | DL |
| 19 | apocrine adenosis of breast | 91.01% | DL |
| 20 | blunt duct adenosis of breast | 91.01% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.